TY-302

· TYK Medicines, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TY-302, covering 2025-08-05 to 2025-08-05. Get the full timeline:

Most recent: Clinical Trial Update: Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） [Phase 1, Phase 2]

See pricing